Autosomal Dominant Polycystic Kidney Disease
Conditions
Brief summary
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD) compared to education alone.
Interventions
BEHAVIORALMayo Clinic-Approved Education
Education attention control will be administered by board certified health and wellness coaches via virtual coaching sessions.
BEHAVIORALDigital Neuropathy
The web-based system (REJUVENATE) consists of a set of cognitive exercises continuously and automatically adjusted in difficulty based on each user's performance to maintain the balance of challenge and success optimal to promote neuroplastic enhancement of target neural systems.
BEHAVIORALCapacity Coaching
Board certified health and wellness coaches will create a plan with subjects to use capacity, defined as patients' abilities and resources, to do self-management work.
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed clinical diagnosis of ADPKD using Pei-Ravine criteria * Pre-End Stage Kidney Disease, with Stage 1-5 CKD (eGFR \>10 ml/min/1.73m2, with no anticipated dialysis or transplant within 12 months) * Clinical or self-diagnosis of depression * English-language fluency
Exclusion criteria
* Suicidal ideation/unstable mental illness of any kind * Lack of access/ability to use internet-based programs * eGFR \<10 ml/min/1.73m2 * Anticipated dialysis or transplant within 6 months * Prior chronic dialysis * Prior organ (liver or kidney) transplant * Lack of English language fluency * Significant cognitive impairment (Mini Mental Status Exam (MMSE))
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Actual use of intervention | 12 weeks | Actual use of each intervention will be reported as the percentage of eligible subjects participating in the assigned interventions at least twice a week for at least 20 minutes per session. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Montgomery-Asberg Depression Rating Scale (MADRS-S) score | Baseline, 12 weeks | The Montgomery-Asberg Depression Rating Scale (MADRS-S) is a 9-item patient-administered questionnaire designed to measure the severity of depression. It evaluates symptoms like sadness, tension, sleep, appetite, concentration, and suicidal thoughts, with scores ranging from 0 to 54, where higher scores indicate greater severity |
Countries
United States
Contacts
CONTACTRyan Helland, CCRP
PRINCIPAL_INVESTIGATORNeera Dahl, MD, PhD
Mayo Clinic
Outcome results
None listed